PRIA Logo™
119-hr-661119th CongressWALLET

MIRACLE Medical Technology Act of 2025

Sponsored By: Representative Buchanan, Vern [R-FL-16]

Introduced

Summary

A U.S.–Israel health care collaboration program would coordinate joint research, regulatory alignment, and shared manufacturing to speed new medical products, digital health tools, and disease‑prevention solutions into use.

Show full summary
  • Patients and families could get faster access to treatments, vaccines, and early‑stage clinical trials thanks to coordinated R&D and disease‑prevention work.
  • Startups and innovators would gain support for technology transfer, innovation hubs, and market adoption, with attention to data sharing, cybersecurity, and commercialization pathways.
  • Regulators, manufacturers, and the workforce would see efforts toward regulatory harmonization, stronger intellectual property protections, possible mutual GMP recognition, joint U.S. manufacturing sites, and training to boost supply‑chain resilience.

*Authorizes $8.0 million per year for fiscal years 2026–2030 to carry out the program, with all spending subject to future appropriations.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

US-Israel health research program and funding

If enacted, HHS would set up a US‑Israel program to speed health research and delivery. It would support joint R&D, medical devices and drugs, digital health and telemedicine, and early trials. It could also back US manufacturing, workforce training, data sharing with Israel’s health ministry, and supply‑chain planning. HHS would consult with Commerce, CMS’s innovation council, and FDA, and begin within 6 months. Congress would authorize $8 million per year for FY2026–FY2030; money would flow only if later appropriated and would mainly aid researchers, start‑ups, and manufacturers.

Sponsors & CoSponsors

Sponsor

Buchanan, Vern [R-FL-16]

FL • R

Cosponsors

  • Rep. Soto, Darren [D-FL-9]

    FL • D

    Sponsored 1/23/2025

  • Rep. Miller-Meeks, Mariannette [R-IA-1]

    IA • R

    Sponsored 1/23/2025

  • Rep. Suozzi, Thomas R. [D-NY-3]

    NY • D

    Sponsored 12/23/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation